New study highlights risks of anti-TNF antibody class

A new study in the Journal of the American Medical Association concludes that people taking Abbott Laboratories' Humira or Johnson & Johnson's Remicade--both blockbuster meds--face triple the risk of cancer and double the risk of infections. While the chances of getting either cancer or an infection are still small, the study's authors conclude, these anti-TNF antibody drugs still pose threats that people should consider carefully. The drug makers responded by saying that the new study does not conclusively prove that the drugs are responsible for the added risks and that the research is flawed.

- read this article on the study from the Chicago Tribune